– Additional Phase 3 PURPOSE data reinforce the safety profile of twice-yearly Yeztugo® as an effective HIV prevention option across diverse populations –
– New data show higher treatment satisfaction after switching from IM CAB+RPV to…
Gilead to spotlight new virology data across HIV, viral hepatitis and respiratory diseases at IDWeek 2025
